

## BOARD AND MANAGEMENT UPDATE

---

Bio-Gene Technology Limited (**Bio-Gene** or the **Company**), an agtech development company enabling the next generation of novel insecticides, announces the following changes to the Board and management:

- Non-Executive Director, Mr. James Joughin brings forward his previously announced resignation effective immediately.
- Non-Executive Director, Dr. Peter Beetham resigns effective immediately, and will join the Bio-Gene Scientific Advisory Board.
- Managing Director and CEO, Richard Jagger has given notice that he wishes to transition from the full time CEO role to an ongoing consultancy and advisory role once a replacement is found and he has provided a suitable hand over.
- Board reviewing potential candidates for the CEO role and open Non-Executive Director positions.

As announced on 21 March 2023, Mr James Joughin indicated that due to increasing commitments associated with his Chairmanship and director roles on other ASX-listed and private companies, his intention was to retire from the Bio-Gene Board effective 30 June 2023. James has now advised that given his workload on other companies has increased significantly he will leave the Bio-Gene Board to concentrate on these other activities, effective immediately.

Dr. Peter Beetham has advised that he too will be stepping down from the Board, effective immediately, to concentrate on his executive role at Cibus, following the definitive merger agreement of Calyxt (NASDAQ:CLXT) with Cibus. The new company, following the merger close, will require him to take on a lead role in the combination of two leading companies in the Agricultural Gene Editing industry. The Company has appointed Peter to our Scientific Advisory Board, joining Professor Cate Hill from Purdue University.

Chairman Robert Klupacs said: *“On behalf of the Board and management, I sincerely thank James and Peter for their outstanding contributions to Bio-Gene over their tenure.- Both are seasoned professionals and experts in their fields and Bio-Gene was fortunate to have their expertise on the Board.I am pleased that Peter has agreed to join our Scientific Advisory Board and will join Professor Cate Hill in guiding the Company on its scientific endeavours. Peter has a PhD in plant science and 30 years of experience in nurturing new technologies, as well as building a highly successful biotech business from the ground up. His continued involvement as a scientific advisor will be very valuable as we continue to commercialise our product suite.”*

Mr. Richard Jagger, Managing Director and CEO of Bio-Gene, has formerly advised the Board that he wishes to allow for an orderly transition within the Company, that will see him step down as CEO to a supporting role focused on stakeholder management of Bio-Gene’s existing and future development partnership relationships. The timing of this transition will be confirmed over coming months.

Mr. Klupacs said: *“Richard has played a major role since the IPO in overseeing the development of the Company, completing our commercials deals, and developing the inherent value of our technology. The Board has been discussing Richard’s personal needs with him for some time, and has accepted his transition proposal which will allow him to stay involved in the Company and help guide our commercial partnerships and key stakeholder relationships. We are pleased he will remain a significant member of the Bio-Gene team in a more focussed role that suits his changed personal circumstances.”*

The Company has already begun a review of its skills matrix within the Board and is developing a list of potential Board member candidates. In addition, an international search for a replacement CEO is underway.

Approved for release by the Board of Directors

- ENDS -

**For further information, please contact:**

Bio-Gene Technology Limited:  
E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

Adrian Mulcahy, Investor Relations  
E: [adrian.mulcahy@automicgroup.com.au](mailto:adrian.mulcahy@automicgroup.com.au)  
M: 0438 630 422

Tristan Everett, Media Relations  
E: [tristan.everett@automicgroup.com.au](mailto:tristan.everett@automicgroup.com.au)  
M: 0403 789 096

**About Bio-Gene Technology Ltd**

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

**Flavocide™ and Qcide™** are trademarks of Bio-Gene Technology Limited.